• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

The PIONEER-HF Trial: Sacubitril-valsartan linked to superior outcomes in acute decompensated heart failure

byJames RoebkerandDayton McMillan
February 12, 2019
in Cardiology, Emergency
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Among patients hospitalized for acute decompensated heart failure with reduced ejection fraction (HFrEF), treatment with sacubitril-valsartan reduced N-terminal pro-B type natriuretic peptide (NT-proBNP) greater than treatment with enalapril.

2. There was no significant difference in the rate of worsening renal function, hyperkalemia, symptomatic hypotension, or angioedema between either treatment group.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: While the landmark PARADIGM-HF trial demonstrated that the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril-valsartan had superior clinical outcomes in patients with HFrEF compared to the angiotensin-converting enzyme inhibitor (ACEi) enalapril, patients with acute decompensated HF were excluded. Given this population comprises a large part of clinical practice, the PIONEER-HF trial was conducted to analyze the efficacy and safety of ARNI therapy in patients with HFrEF hospitalized for acute decompensated HF. The authors reported a significantly greater reduction in NT-proBNP concentration, the primary outcome, in patients treated with sacubitril-valsartan compared to enalapril. Among key safety outcomes, there was no significant difference in the rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema between the sacubitril-valsartan and enalapril groups. The results of this trial extend the conclusions drawn from PIONEER-HF, and suggest ARNI therapy is a safe and effective strategy in HFrEF patients who present with acute decompensated HF.

This was a multicenter, randomized trial with a large and diverse patient population. It provided high level evidence of ARNI therapy in the inpatient HFrEF population, which was previously absent. The trial was limited by the high rate of medication discontinuation and high percentage of missing data. Furthermore, translation to clinical practice is limited by the strict requirements for sacubitril-valsartan initiation (including a 36-hour medication washout period) set by the authors, which may increase hospital stay. Future studies will need to look at potential outcome benefits of treatment with sacubitril-valsartan in patients with decompensated heart failure.

Click to read the study in NEJM

Click to read an accompanying editorial in NEJM

RELATED REPORTS

#VisualAbstract: Effectiveness of sacubitril-valsartan in post-myocardial infarction management compared to ramipril

Effectiveness of sacubitril-valsartan in post-myocardial infarction management

Hemodynamic-guided management of heart failure may reduce hospitalization rates

Relevant Reading: Angiotensin-neprilysin inhibition versus enalapril in heart failure

In-Depth [randomized controlled trial]: This was a multicenter trial that randomized 881 patients with HFrEF to sacubitril-valsartan (n=440) or enalapril (n=441) therapy. Primary outcome data, the time-averaged proportional change in the NT-proBNP concentration from baseline through weeks 4 and 8, was available for 349 (79.3%) of patients in the sacubitril-valsartan group and 348 (78.9%) in the enalapril group. Key safety outcomes included incidences of worsening renal function (increase in creatinine Âł0.5 mg/dL and decrease in estimated glomerular filtration rate Âł25%), hyperkalemia (Âł5.5 mmol/L), symptomatic hypotension, and angioedema.

Excluding discontinuation due to death, the trial medication was stopped early in 87 (19.6%) patients in the sacubitril-valsartan group and 90 (20.3%) patients in the enalapril group. The time-averaged reduction in NT-proBNP concentration obtained at weeks 4 and 8 was significantly greater in the sacubitril-valsartan group than enalapril group (percent change, -46.7% vs. -25.3%, respectively; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% confidence interval [CI], 0.63 to 0.81; P<0.001). This result was evident by week 1 (ratio of change, 0.76; 95% CI, 0.69 to 0.85). There was no difference between the two treatment groups in the rates of worsening renal function (relative risk [RR] between sacubitril-valsartan vs. enalapril, 0.93; 95% CI, 0.67 to 1.28), hyperkalemia (RR, 1.25; 95% CI, 0.84 to 1.84), symptomatic hypotension (RR, 1.18; 95% CI, 0.85 to 1.64), or angioedema (RR, 0.17; 95% CI, 0.02 to 1.38).

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

 

 

Tags: acute decompensated heart failureARNIEnalaprilsacubitril-valsartan
Previous Post

2 Minute Medicine Rewind February 11, 2019

Next Post

Paracetamol plus ibuprofen significantly reduces post-operative morphine use in total hip arthroplasty patients

RelatedReports

StudyGraphics

#VisualAbstract: Effectiveness of sacubitril-valsartan in post-myocardial infarction management compared to ramipril

February 10, 2022
Patient Basics: Heart Attack (Myocardial Infarction)
Cardiology

Effectiveness of sacubitril-valsartan in post-myocardial infarction management

February 3, 2022
Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis
Cardiology

Hemodynamic-guided management of heart failure may reduce hospitalization rates

September 22, 2021
HOSPITAL score predicts risk of 30-day potentially avoidable readmission to hospital
Cardiology

Achieving NP predischarge thresholds associated with reduced heart failure mortality and readmission

November 29, 2016
Next Post
Long-term Acetaminophen Use in Pregnancy and ADHD

Paracetamol plus ibuprofen significantly reduces post-operative morphine use in total hip arthroplasty patients

Earlier puberty associated with increased risk of depression in girls

USPSTF: Counseling interventions likely to prevent perinatal depression

Addressing non-obesity related barriers may improve bariatric surgery effectiveness

Symptomatic and non-symptomatic heart failure associated with increased postoperative mortality in non-cardiac elective surgery

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options